Total homocysteine lowering artery disease patients in the treatment among coronary era of folic acid-fortified cereal grain flour

被引:21
作者
Bostom, AG
Jacques, PF
Liaugaudas, G
Rogers, G
Rosenberg, IH
Selhub, J
机构
[1] Rhode Isl Hosp, Div Renal Dis, Providence, RI 02903 USA
[2] Mem Hosp Rhode Isl, Pawtucket, RI USA
[3] Tufts Jean Mayer USDA Human Nutr Res Ctr, Vitamin Bioavailabil Lab, Boston, MA USA
关键词
B vitamins; randomized trial; treatment efficacy;
D O I
10.1161/hq0302.105369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of deficient plasma folate status and elevated total plasma levels of homocysteine (tHcy), have been dramatically reduced after fortification of all enriched cereal grain flour products with folic acid at 140 mug/100 g flour. Against this new background fortification, we evaluated the tHcy-lowering efficacy of pharmacological dose, folic acid-based vitamin B supplementation among stable coronary artery disease (CAD) patients. Using a 2x2 factorial design, 1,31 stable CAD patients (mean age 60.1 years; 29.8% women) were randomly assigned to receive a combination of folic acid 2.5 mg/d, riboflavin 5 mg/d, + B-12 0.4 mg/d, or placebo, with or without vitamin B-6 50 mg/d, for 12 weeks of treatment. ANCOVA adjusted for baseline fasting tHey levels revealed only very modest (ie, approximate to1.0 mumol/L), albeit statistically significant (P<0.05), reductions in mean fasting tHcy levels afforded by the folic acid-containing treatments. Additional analyses indicated that none of the treatments provided a statistically significant reduction in the 2-hour post-methionine increase in tHcy levels, relative to placebo treatment. CAD patients exposed to cereal grain flour products fortified with folic acid who receive high-dose, folic acid-containin a vitamin B regimens, experience only very modest reductions in their mean fasting plasma tHcy levels. These findings have important implications for the statistical power of clinical trials testing the hypothesis that tHcy-lowering treatment may reduce recurrent atherothrombotic event rates.
引用
收藏
页码:488 / 491
页数:4
相关论文
共 29 条
[1]  
[Anonymous], 2004, BIRTH DEFECTS RES A, DOI DOI 10.1002/bdra.20045
[2]   Homocysteine concentrations and methionine loading in patients on antiepileptic drugs [J].
Apeland, T ;
Mansoor, MA ;
Strandjord, RE ;
Kristensen, O .
ACTA NEUROLOGICA SCANDINAVICA, 2000, 101 (04) :217-223
[3]   DETERMINATION OF FREE AND TOTAL HOMOCYSTEINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
ARAKI, A ;
SAKO, Y .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 :43-52
[4]   COLESTIPOL PLUS NIACIN THERAPY ELEVATES PLASMA HOMOCYST(E)INE LEVELS [J].
BLANKENHORN, DH ;
MALINOW, MR ;
MACK, WJ .
CORONARY ARTERY DISEASE, 1991, 2 (03) :357-360
[5]  
BOSTOM AG, 1995, CLIN CHEM, V41, P948
[6]   Treatment of hyperhomocysteinemia in renal transplant recipients - A randomized, placebo-controlled trial [J].
Bostom, AG ;
Gohh, RY ;
Beaulieu, AJ ;
Nadeau, MR ;
Hume, AL ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (12) :1089-1092
[7]   Homocysteine and arteriosclerosis - Subclinical and clinical disease associations [J].
Bostom, AG ;
Selhub, J .
CIRCULATION, 1999, 99 (18) :2361-2363
[8]   IMPAIRED HOMOCYSTEINE METABOLISM IN EARLY-ONSET CEREBRAL AND PERIPHERAL OCCLUSIVE ARTERIAL-DISEASE - EFFECTS OF PYRIDOXINE AND FOLIC-ACID TREATMENT [J].
BRATTSTROM, L ;
ISRAELSSON, B ;
NORRVING, B ;
BERGQVIST, D ;
THORNE, J ;
HULTBERG, B ;
HAMFELT, A .
ATHEROSCLEROSIS, 1990, 81 (01) :51-60
[9]   Serum homocysteine increases after therapy with fenofibrate or bezafibrate [J].
Dierkes, J ;
Westphal, S ;
Luley, C .
LANCET, 1999, 354 (9174) :219-220
[10]   Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].
Eikelboom, JW ;
Lonn, E ;
Genest, J ;
Hankey, G ;
Yusuf, S .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375